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Abstract 
Background: Photothermal therapy (PTT) is an emerging anti‑cancer therapeutic strategy that generates hyper‑
thermia to ablate cancer cells under laser irradiation. Gold (Au) coated liposome (AL) was reported as an effective 
PTT agent with good biocompatibility and excretory property. However, exposed Au components on liposomes can 
cause instability in vivo and difficulty in further functionalization.
Results: Herein, we developed a theranostic dual‑layered nanomaterial by adding liposomal layer to AL (LAL), fol‑
lowed by attaching polyethylene glycol (PEG) and radiolabeling. Functionalization with PEG improves the in vivo 
stability of LAL, and radioisotope labeling enables in vivo imaging of LAL. Functionalized LAL is stable in physiological 
conditions, and 64Cu labeled LAL (64Cu‑LAL) shows a sufficient blood circulation property and an effective tumor tar‑
geting ability of 16.4%ID  g−1 from in vivo positron emission tomography (PET) imaging. Also, intravenously injected 
LAL shows higher tumor targeting, temperature elevation in vivo, and better PTT effect in orthotopic breast cancer 
mouse model compared to AL. The tumor growth inhibition rate of LAL was 3.9‑fold higher than AL.
Conclusion: Based on these high stability, in vivo imaging ability, and tumor targeting efficiency, LAL could be a 
promising theranostic PTT agent.
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Background
Photothermal therapy (PTT) is one of the rising cancer 
therapeutics which utilizes the combination of photo-
absorbers and near-infrared (NIR) light irradiation to 
generate hyperthermia and eliminate cancer cells [1, 2]. 
PTT has multiple advantages over conventional can-
cer therapeutics, such as high tumor selectivity, ease of 
therapeutic dose adjustment, less invasiveness, and low 
likelihood of resistance [3–6]. The high selectivity of PTT 
can be achieved both by the specific tumor targeting of 
photo-absorbers and the localized light administration. 
In addition, the tumor tissues have an insufficient blood 
supply and low heat resistance than normal tissues and 
therefore are more sensitive to PTT [7]. PTT has been 
proven to effectively treat various animal models of 
malignant tumors including glioblastoma, breast can-
cer, lung cancer, and colorectal cancer [8]. Furthermore, 
a recent pilot clinical trial demonstrated that the intra-
tumorally injected Au-silica nanoshells-mediated PTT 
was successful for the ablation of prostate cancer in 94% 
(15/16) of patients without significant adverse events [9].
Gold nanoparticles (Au NPs) are considered one of the 
most promising photo-absorbers for PTT because of the 
excellent photothermal conversion efficiency and tun-
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surface plasmon resonance phenomenon, Au NPs have 
an unprecedently fast and efficient photothermal conver-
sion than organic photo-absorbers [13]. Also, the absorp-
tion band of Au NPs can be easily adjusted to match the 
emission band of the light source by modifying the size, 
shape, and compositions of the NPs [14]. However, there 
are drawbacks of Au NPs, which are (1) low tumor target-
ing ability due to short circulation time, (2) potential tox-
icity due to long-term retention in the body system, and 
(3) difficulty of non-invasive assessment of biodistribu-
tion. Although Au is considered an inert and biocompat-
ible material, the accumulation of Au in the body system 
can lead to considerable health risks [15]. The toxicity 
of Au NPs increases with dose and time [16–19]. When 
Au NPs are administered to the body system, serum pro-
teins actively interact with Au NPs to produce a protein 
corona surrounding Au NPs [20, 21]. As a result, Au NPs 
are opsonized and easily phagocytosed up by the reticu-
loendothelial system (RES) [22–26]. This leads to the fast 
clearance of the NPs from the circulation and low tumor 
targeting efficacy [27]. Also, Au NPs taken up by RES are 
not excreted in a reasonable timeframe and may cause 
toxicity [28]. Therefore, Au NPs with high extractability 
and efficient tumor targeting ability are highly desired for 
successful clinical translation of Au NP mediated PTT. 
In 2015, Rengan et  al. [29] synthesized the Au coated 
liposome (AL) that can be excreted from the system effi-
ciently. Au coated liposome can be excreted from the sys-
tem because the Au component of the NPs is decorated 
over the liposome rather than forming a solid core, ena-
bling the break down of the Au decorated liposome in the 
cells. The authors found that most of the Au components 
can be excreted within 14  days after intravenous (iv.) 
injection of the NPs. Also, the NP showed in  vivo PTT 
effect after intratumoral injection of the NPs. However, 
in the biodistribution study, the NPs were rapidly taken 
up by RES (52%ID in liver at day 1) after iv. injection, sug-
gesting the limited ability of the NPs to the target tumor. 
Also, in  vivo PTT after iv. injection of AL was not per-
formed [29].
Herein, we developed theranostic dual-layered NPs 
by adding liposomal layer to AL (liposomal AL, LAL) 
which has enhanced tumor targeting ability compare to 
AL (Scheme 1). The NPs are further functionalized by the 
help of the additional liposome layer; (1) radiolabeling 
for in vivo imaging enabling theranostics and (2) adding 
polyethylene (PEG) group to enhance in vivo stability and 
passive targeting ability. We found that LAL was more 
stable than AL in vitro and in vivo. LAL has a similarly 
good photothermal effect with AL. Also, non-invasive 
quantitative imaging could be done using 64Cu-LAL. 
Intravenously injected LAL showed long circulation time 
and excellent tumor targeting efficiency by passive tar-
geting (16.4%ID  g−1) in the orthotopic mouse model of 
breast cancer. LAL showed 2.9-fold higher in vivo tumor 
targeting ability than AL based on in  vivo fluorescence 
imaging study. Finally, in  vivo tumor growth inhibition 
rate of LAL mediated PTT was 3.9-fold higher than that 
of AL mediated PTT (79.4% vs. 20.4%, respectively).
Results and discussion
Characterization of LAL and AL
The functionalized outer liposomal layer was success-
fully self-assembled over AL. In transmission elec-
tron microscopy (TEM) images, the Au decoration 
on liposome was observed in the AL sample, and the 
successfully covered outer liposomal layer over the 
AL was observed in the LAL sample (Fig.  1a, b). TEM 
based sizes of AL and LAL were 61.02 ± 29.22 nm and 
72.84 ± 22.49  nm, respectively (n = 20, mean ± s.d.). 
Hydrodynamic sizes of AL and LAL were recorded 
3 times in phosphate-buffered saline (PBS) using 
Scheme 1 Schematic illustration of experimental procedure of LAL for photothermal therapy (PTT) and 64Cu labeled LAL (64Cu‑LAL) for in vivo 
imaging
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dynamic light scattering (DLS). Hydrodynamic size 
of the LAL was 67.32 ± 22.65  nm and the three meas-
urements were almost identical to each other (Addi-
tional file  1: Figure S2a). The hydrodynamic size of 
AL was measured differently in the three repeated 
measurements: 109.5 ± 52.92  nm, 73.44 ± 41.24  nm, 
and 49.38 ± 26.95  nm, respectively (Additional file  1: 
Figure S2b). This could be caused by the instability of 
AL in PBS. The zeta potential of the inner liposome 
was −  12.0  mV, which is a typical surface potential of 
liposomes in the literature [30]. The decreased zeta 
potential, − 23.7 mV, was observed in AL which can be 
indirect evidence of successful Au coating to the lipo-
some since bare Au NPs have low zeta potential ranging 
from − 20 to − 40 mV [23, 31, 32]. As AL covered one 
more liposomal layer, the zeta potential was elevated to 
− 17.7 mV because of the PEG moiety of the outer lipo-
somal layer (Fig.  1c). This further confirms successful 
PEGylation over AL since PEGylation has an impact of 
lowering negative zeta potential [23, 31–33].
Size stability of LAL in various solutions
The stabilities of the LAL were tested in various physi-
ological solutions [deionized water (DW), PBS, and cell 
media with 10% fetal bovine serum (FBS)] to determine 
the feasibility of in  vivo utilization of the LAL. LAL 
showed no visible aggregates or precipitates and main-
tained its size ranging from 60 to 80 nm in DW, PBS, and 
cell media with 10% FBS for 14 days (Fig. 1d, Additional 
file  1: Figures  S1, S2a). On the other hand, AL became 
unstable in those conditions showing a large range of 
size variation starting from 24  h after the incubation 
(Additional file  1: Figure S2b). PEGylated outer lipo-
somal layer increased the stability of LAL diminishing 
ionic and serum protein interactions. This result sug-
gests that LAL has excellent stability in physiological 
solutions, which is a prerequisite for in vivo tumor tar-
geting of NPs.
In vitro photothermal effect of LAL
Both AL and LAL had a broad absorbance band that 
starts from 600 nm and has a peak at 900 nm (Fig. 2a). 
The temperature elevation under the 1 W 808 nm laser 
irradiation for 40  min presented that AL and LAL had 
efficient photothermal conversion abilities. The tem-
peratures of the AL and LAL solutions increased from 
25.1 ± 0.6  °C to 42.3 ± 0.4  °C, and from 25.8 ± 0.4  °C 
to 44.2 ± 1.3  °C, respectively, for 40  min (Fig.  2b, Addi-
tional file 1: Figure S3). Of note, AL and LAL contained 
the same Au concentration, 23.7  μg   mL−1. The temper-
ature of DW and liposome solution without Au slightly 
increased from 26.2 ± 0.3  °C to 28.2 ± 0.4  °C, and from 
25.6 ± 0.6  °C to 29.2 ± 0.3  °C, respectively, under the 
same laser irradiation condition. After the irradiation, 
AL and LAL temperature changes were 17.2 ± 0.7 °C and 
18.3 ± 1.0  °C, respectively, showing no significance. AL 
and LAL were similarly effective in photothermal con-
version. We also observed that the photothermal effect 
increased proportionally to the Au concentration in LAL 
solution (Fig.  2c, Additional file  1: Figure S3). Both AL 
and LAL showed stable temperature elevation during 
the four repeats of laser irradiation on/off cycle, allowing 
them to be used for multiple courses of PTT with single 
injection in practical applications (Fig.  2d). The photo-
thermal conversion efficiency (η) of AL and LAL were 
calculated by the following Eq. 1 [34, 35].
where, Tmax is the highest temperature of NP solution, 
and Tsur is the initial temperature of NP solution. Qdiss is 
the heat dissipation, and I represents the power of laser. 
A is the absorbance at 808  nm, m is the weight of NP 
solution, and c represents the specific heat capacity of 












Fig. 1 Characterization of AL and LAL. Transmission electron microscopy (TEM) images of a AL and b LAL. Scale bars are 50 nm. c Surface zeta 
potential values of liposome, AL, and LAL (n = 3, mean ± s.d.). d Stability test of LAL in deionized water (DW), phosphate‑buffered saline (PBS), and 
RPMI 1640 with 10% fetal bovine serum (FBS) (n = 3, mean ± s.d.)
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where, θ refers to the dimensionless driving force, and t 
represents the corresponding time.
Figure  2e, f were used to derive τs values of AL and 
LAL. The calculated photothermal efficiency values of 
AL and LAL were 34.13% and 37.46%, respectively, show-
ing that the photothermal efficiency of LAL was slightly 
higher than AL. These results could be competitive with 
the photothermal conversion efficiency of other photo-
thermal Au nanomaterials such as Au nanorod (21–22%) 
[36, 37], Au nanoshell (13%) [38], Au nanofluid (20–21%) 
[39], Au nanovesicles (18%) [36, 40] and other Au nano-
materials (30–31%) [37, 41].
Excellent in vitro PTT effect of LAL
The cytotoxicities of LAL and AL were assessed 
(Fig.  3a). AL and LAL showed no overt cytotoxic-
ity showing over 80% survival of the cells up to Au 
concentrations of 11.85  μg   mL−1. In previous studies 
that utilized Au NP for cancer therapeutics, the con-
centration of Au was ranged from 15 to 200  μg per 
mouse (about 20  g) [42–48]. Therefore, both AL and 
LAL are reasonably biocompatible compare to previ-
ously reported studies. In  vitro PTT effects of LAL 
and AL were compared in a triple-negative breast can-
cer cell line, 4T1 cell line, under the NIR irradiation. 
After the NIR laser irradiation to LAL incubated cells, 
tumor cell death was observed even at a low Au con-
centration of 0.47  μg   mL−1 (Fig.  3b). Also, under the 
laser irradiation, LAL had higher cancer cell killing 
effect than the AL at all Au concentrations (from 0.47 
to 4.74  μg   mL−1) except the highest concentration, 
11.85  μg   mL−1. The in  vitro PTT effects were signifi-
cantly higher in LAL than AL at Au concentration of 
1.18, 2.37, and 4.74  μg   mL−1 (Fig.  3b) (P = 0.000745, 
P = 0.0000552, and P = 0.0162, respectively).
We explored the potential reasons for the significant 
difference of in  vitro PTT effect between LAL and AL. 
Firstly, we compared the photothermal effect of AL and 
LAL in the physiological solution (RPMI 1640) to emu-
late in vitro situations (Additional file 1: Figure S4). After 
40-min-irradiation, AL and LAL temperature changes 
were 21.4 ± 0.23  °C and 24.2 ± 1.65  °C, respectively. The 
temperature change of LAL was considerably higher than 
AL (P = 0.045). Because the efficient cell uptake of NP 
helps obtain maximum PTT effect, the cell uptake ability 
was compared using rhodamine 6G (R6G) loaded AL and 
LAL [49]. Cellular uptake of AL and LAL was observed 
in the red fluorescence images (Fig.  3c). We found that 
the fluorescence signal of the internalized LAL was sig-
nificantly higher than that of internalized AL (P = 0.0163) 
(Fig. 3d). Finally, we compared the degree of DNA dam-
age between AL and LAL based PTT. The PTT caused 
DNA damages were observed using a DNA-double 
strand breaks (DSBs) marker, γ-H2AX foci. DNA-DSBs 
of 4T1 cells were rarely detected in the 4T1, 4T1 + laser, 
AL, and LAL groups (Fig. 3e). AL + laser and LAL + laser 
exhibited much severe DNA damages in cells than the 
laser non-irradiated AL and LAL (P < 0.001). The number 
of γ-H2AX foci tended to be higher in the LAL + laser 
cells than the AL + laser cells (P < 0.05) (Fig. 3f ).
Fig. 2 Photothermal effect of AL and LAL. a Absorbance spectra of liposome, AL, and LAL. b Photothermal effect by observing temperature 
evaluation of DW, liposome, AL, and LAL under the 808‑nm laser irradiation with 1 W intensity for 40 min (n = 3, mean ± s.d.). c Au concentration 
dependent photothermal effect of LAL under the 808‑nm laser irradiation with 1 W intensity for 40 min (n = 3, mean ± s.d.). d Verification of thermal 
stability of AL and LAL during the 4 repeats of laser on/off cycle. e Time constant for heat transfer of e LAL and f AL from the photothermal system
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Taken together, we found that LAL and AL both had 
excellent in vitro PTT effects and the PTT effect of LAL 
was higher than AL. The higher in  vitro PTT effect of 
LAL on 4T1 cells than AL could be attributed to the 
higher cellular uptake, DNA damage, and photothermal 
effect in the physiological solution of LAL than AL.
Fig. 3 In vitro PTT results of AL and LAL. Cell viability of 4T1 treated AL and LAL a without laser and b with the 2 W  cm−2 laser irradiation for 5 min 
(n = 4, mean ± s.d.). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Data were analyzed by one‑way ANOVA with Tukey’s post‑test. c Confocal 
images of AL and LAL internalized in 4T1 cells. All scale bars in the images are 50 μm. TD: transmitted light channel, blue: nuclei (Hoechst 33342), 
green: cytoskeleton  (ViaFlour® 488), red: LAL or AL (R6G). d The quantified fluorescence intensity of each cell where AL or LAL internalized (n = 14, 
mean ± s.d.). Data were analyzed by Student’s t‑test. *P < 0.05. e The fluorescence images representing 4T1 cell nuclei to observe DNA‑DSBs by 
the γ‑H2AX foci after the laser irradiation (808‑nm laser, 2.5 W  cm−2, 5 min). Blue: nuclei (Hoechst 33342), green: γ‑H2AX focus (Alexa Flour 488). All 
scale bars in the images are 10 μm. f DNA‑DBSs quantitative analysis in 4T1 cells with and without laser irradiation (n = 5, mean ± s.d.). *P < 0.05, 
***P < 0.001. Data were analyzed by one‑way ANOVA with Tukey’s post‑test
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In vivo fluorescence imaging and quantitative analysis
We assessed the tumor targeting abilities of AL and LAL 
in the 4T1 orthotopic breast cancer mouse model using 
in vivo fluorescence imaging. The same 20 μg of Au was 
injected to each mouse. For the in  vivo fluorescence 
imaging, fluorescent AL and LAL were prepared using 
1,1ʹ-dioctadecyl-3,3,3ʹ,3ʹ-tetramethylindotricarbocyanine 
iodide (DiR) labeled inner liposome. The imaging was 
performed up to 24  h after iv. injection of the NPs. 
DiR labeled LAL, and AL showed high liver and tumor 
uptakes. However, the tumor uptakes were more promi-
nent in LAL injected mice than AL injected mice (Fig. 4a, 
b and Additional file 1: Figure S5). The mice were sacri-
ficed after 24  h and the major organs and tumors were 
extracted. The fluorescence signals of the major organs 
and the tumors were quantified. Tumor to normal organ 
ratios were significantly higher in LAL than AL. The 
tumor to liver, spleen and lung ratios of LAL were 2.9, 
2.6, and 1.7 folds higher than those of AL (Fig.  4c–e). 
We assumed that the additional liposomal layer of LAL 
enhanced the in  vivo stability and caused the higher 
tumor uptake of the NPs.
Radiolabeling efficiency and radiostability of 64Cu‑LAL
A further modification cannot be applied easily in AL 
because of the decorated Au component on the liposome. 
In general, Au-thiol affinity was used for the function-
alization of Au NPs, however, thiol moiety of Au-thiol 
can be easily replaced by glutathione (GSH) or other 
proteins [20, 32, 50, 51]. This leads to a detachment of 
radiolabeled-ligand, which causes uncertainty of Au 
in  vivo biodistribution information. Thus, AL could not 
be radiolabeled and used in  vivo with Au-thiol interac-
tion. However, an additional lipid bilayer of LAL with 
Fig. 4 In vivo fluorescence images and assessment of passive tumor targeting efficacy of DiR labeled LAL and AL in 4T1 tumor bearing mouse 
model (n = 4). a In vivo fluorescence images of 4T1 breast cancer bearing mouse model at 0, 2, 12, and 24 h. DiR labeled LAL (left column) and 
AL (right column) injected mice. White arrows indicate tumors. b Representative ex vivo fluorescence images of tumors and main organs (He: 
heart, Li: liver, Sp: spleen, Ki: kidney, and Lu: lung) resected from each mouse after in vivo imaging. Comparison of tumor to non‑targeted organ, c 
liver, d spleen, and e lung ratio. Tumor targeting efficiency comparison with non‑targeted organ, c liver, d spleen, and e lung. Data were analyzed 
statistically with a Student’s t‑test. *P < 0.05, ***P < 0.001, ****P < 0.0001
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1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) ena-
bled further functionalization for radiolabeling with 64Cu. 
The radiolabeling efficiency of 64Cu-LAL in PBS was 94%, 
and the radiochemical stabilities were maintained at 90% 
and 88% after 2 and 24 h from the radiolabeling (Fig. 5b). 
With these results of high radiostability, we utilized 64Cu-
LAL to evaluate the tumor targeting efficiency of LAL by 
in vivo PET imaging.
In vivo PET imaging and quantitative in vivo 
biodistribution analysis
In vivo PET images were acquired to demonstrate the 
imaging ability of 64Cu-LAL (4.74  μg of Au) and assess 
the passive tumor targeting efficiency of the 64Cu-LAL 
in the orthotopic breast cancer mouse model (Fig.  5a). 
The PET images showed the long circulation ability and 
effective tumor targeting efficiency of 64Cu-LAL. The 
quantified 64Cu-LAL uptake of major organs in the PET 
images was shown in Fig.  5c. The 64Cu-LAL uptake in 
tumors increased gradually up to 16.4%ID  g−1 after 24 h 
from the injection. The circulation half-life of 64Cu-LAL 
was calculated as 8.03 h (Fig. 5d). Tumor to background 
(heart, liver, spleen, and muscle) ratios exhibited an 
increasing tendency, and the ratios were 1.4, 0.79, 1.3, 
and 23, respectively, after 24  h from then injection 
(Fig. 5e–h). Of note, tumor to liver and tumor to spleen 
ratios based on PET images were similar with the results 
from IVIS imaging. In previous studies, various types 
of Au NPs for PTT were accumulated in tumors rang-
ing from 1.61 to 9.6%ID  g−1 after 12–48  h from the iv. 
injection [52–58]. Bare Au NPs showed the lowest tumor 
accumulation, 1.61%ID  g−1. Most Au NPs were modified 
with PEG, peptides, or proteins, showing over 5%ID  g−1 
and the highest value, 9.6%ID  g−1, was from PEGylated 
Au NPs (Table  1). Our 64Cu-LAL showed significantly 
higher accumulation (16.4%ID  g−1) than previously 
reported Au NPs, which could be attributed to the dou-
ble layers of liposome and successful PEGylation.
Theranostics is a portmanteau word combining diag-
nostics and therapeutics, which referes to agents or 
techniques that couple diagnostic imaging with tar-
geted therapy. The diagnostic imaging coupled with 
Fig. 5 In vivo positron emission tomography (PET) images and assessment of passive tumor targeting efficiency of 64Cu‑LAL. a Representative 
PET images of 4T1 breast cancer bearing mouse model (n = 3) at the different time points (0, 2, 12, and 24 h). White circles indicate tumor. Upper 
row: coronal, lower row: maximal intensity projection (MIP). b Radiochemical stability of 64Cu‑LAL in PBS at 0, 2, and 24 h after radiolabeling. c 
Quantitative analysis of major organs (heart, liver, spleen, and muscle) and tumors from the PET images at each time point (n = 3, mean ± s.d.). d 
The circulation half‑life from the time activity curve of blood pool. Tumor targeting efficiency comparison with non‑targeted organ, e heart, f liver, g 
spleen, and h muscle (n = 3, mean ± s.d.)














































































































































































































































































































































































































































































































































































































































































































































































































































































Page 9 of 16Jeon et al. J Nanobiotechnol          (2021) 19:262  
therapeutics is a valuable tool for precision medicine 
because it could stratify patietns who will respond to 
the therapeutics. We successfully radiolabled LAL and 
obtained in vivo PET imaging of LAL. Also we were able 
to quantify the tumor uptake and organ distribution 
using the PET images. This information could be used for 
deciding and optimizing dose for PTT.
Effective in vivo PTT of LAL
To confirm that the 808-nm laser can occur a photo-
thermal effect in  vivo, we subcutaneously injected the 
NPs into normal BALB/c-nude mice and irradiated the 
laser. In both AL and LAL injected sites, increased tem-
perature was observed, but the temperature change was 
significantly higher in LAL (40.0  °C) than AL (29.5  °C) 
(Additional file  1: Figure S6). This result corresponds 
with the in vitro comparison in physiological solution in 
Additional file 1: Figure S4, but the difference was more 
prominent in  vivo. It has been reported that the aggre-
gation of Au NPs reduces photothermal conversion effi-
ciency [59]. Therefore, we assume that the instability of 
AL caused aggregation in vivo and resulted in a reduction 
of the in vivo photothermal effect.
After validating the above results, we conducted fur-
ther experiments to examine the efficacy of PTT in vivo 
with 4T1 tumor bearing mice by iv. injection with AL and 
LAL (of note, 20  μg of Au per mouse was used in both 
AL and LAL). We divided the mice into six groups for the 
comparison: normal saline (NS) without laser irradiation, 
NS with laser irradiation, AL without laser irradiation, 
AL with laser irradiation, LAL without laser irradia-
tion, and LAL with laser irradiation (NS, NS + laser, AL, 
AL + laser, LAL, and LAL + laser) (Scheme 2). Since the 
tumor uptake is almost plateaued 24  h after the LAL 
injection based on the PET in vivo biodistribution data, 
the first laser irradiation was given 24 h after the injec-
tion. The second laser irradiation was carried out 24  h 
later from the first laser irradiation. While irradiating 
the 808-nm laser, thermal images were obtained (Fig. 6a, 
Additional file  1: Figure S7). The temperature of LAL 
groups prominently elevated to 43.4 °C at the first irradi-
ation and 51.0 °C at the second irradiation, while NS and 
AL groups showed a mild elevation of the temperature 
[37 °C (1st) and 37.5 °C (2nd) in NS group; 39.2 °C (1st) 
and 39.5  °C (2nd) in AL group, respectively] (Fig.  6c). 
As we verified the thermal stabilities of both LAL and 
AL, we also demonstrated the temperature elevation of 
tumor sites, which were laser-irradiated. The tempera-
ture changes of the LAL group were significantly higher 
than those of NS and AL groups on both irradiation (1st 
irradiation, P < 0.01; 2nd irradiation, P < 0.001) (Fig.  6d). 
These substantial temperature changes in LAL group 
induced feverish environments to tumor tissues which 
could provoke tumor cell killing effect through the hyper-
thermia mechanism.
As shown in Fig. 6b, f, and Additional file 1: Figure S8, 
only the LAL with the laser irradiation group showed 
effectively suppressed tumor growth among the six 
groups. The AL, LAL, NS + laser, and AL + laser groups 
showed similar tumor growth with the control NS group. 
The tumor growth inhibition rate is defined following 
equation, (1 −  (mean volume of treated tumors)/(mean 
volume of control tumors)) × 100% [60]. With this defini-
tion, the tumor growth inhibition rate of each group is as 
follows: NS + laser was 12.2%, AL was 14.2%, AL + laser 
was 20.4%, LAL was 7.52%, and LAL + laser was 79.4% 
(Fig.  6e). Both tumor volume and tumor growth inhibi-
tion rate showed that LAL with PTT was far more effec-
tive than AL with PTT. LAL + laser group also showed 
a significantly higher therapeutic effect in tumor sec-
tioned images (Additional file 1: Figure S9). Furthermore, 
we assessed the in  vivo toxicity of the NPs by observa-
tion of the histology of major organs after the PTT and 
found that there were no visible damages in the heart, 
liver, spleen, kidney, and muscle (Additional file  1: Fig-
ure S9). Taken together, LAL was more effective at 
inhibiting tumor growth than AL. This is because LAL 
has improved stability compared to AL, resulting in sus-
tained photothermal effects in vivo and increased tumor 
passive targeting efficiency. As the functionalized outer 
liposomal layer stabilized LAL in in  vivo environment, 
enhanced permeability and retention (EPR) effect of 
LAL could be remarkably increased. Photothermal effect 
was also higher in the LAL treated mice, since LAL were 
concentrated in the tumor much more than AL. Conse-
quently, more efficient anti-tumor effect was observed in 
PTT with LAL.
LAL showed high tumor targeting in both fluores-
cence images and PET images with its passive targeting 
ability only. The delivery efficacy of LAL, nevertheless 
Scheme 2 Schematic illustration of in vivo PTT in orthotopic 4T1 
tumor bearing mice injected NS, AL, and LAL. 808‑nm laser was 
irradiated on each tumor site with 2.5 W  cm−1 intensity, and the laser 
irradiation procedure was performed twice after the iv. injection
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LAL has no specific targeting moiety, is in the top 8.6% 
(21st) among the previously reported NPs according to 
the review paper (Additional file 1: Figure S10) [61]; the 
review covers NPs with passive or active targeting abil-
ity. As a one way to maximize PTT effect with LAL, 
approaches for active tumor targeting could be consid-
ered by adding target ligands, aptamers, peptides, and 
antibodies [62–64]. A single domain antibody is one of 
the active targeting moieties and have advantages of high 
physicochemical stability, rapid tissue penetration, and 
facile genetic manipulation [65]. Single domain antibod-
ies have been recently used in liposome research which is 
limited in vitro experiments [66–68]. Attaching the active 
targeting moiety to the LAL, which already showed the 
high passive tumor targeting, it is expected to have a syn-
ergistic tumor targeting efficiency.
Another way to increase the PTT effect is using 
immune checkpoint inhibitors (ICI). Recently, NP based 
PTT is attracting more attention as a promising anti-
tumor strategy because of its ability to enhance the 
effect of ICI [69]. The major mechanism to enhance the 
effect of ICI by PTT is to convert immunologically “cold” 
tumor into “hot” tumor, which responds better to ICI. 
Multiple PTT studies using different PTT agents showed 
the synergistic effect with ICI. Indocyanine green (ICG), 
a photothermal agent, loaded poly(lactic-co-glycolic) 
Fig. 6 In vivo PTT results of 4T1 tumor bearing BALB/c mice treated with NS, AL, and LAL. a Representative thermal images of 4T1 breast cancer 
bearing mouse models while the laser irradiated (808‑nm, 2.5 W  cm−2, 5 min). (Upper row: 1st irradiation (24 h after the injection), lower row: 2nd 
irradiation (48 h after the injection)). b Tumor volumes of 4T1 tumor bearing BALB/c mice treated with NS, AL, and LAL. Each treatment group 
was divided into two groups, with or without laser irradiation. (n = 4, mean ± s.d.). Tumor size was measured at 0, 1, 4, 8, 11, 15, and 18 days. c 
Temperature elevation and d the temperature changes of NS, AL, and LAL under the laser irradiation (n = 4, mean ± s.d.). Data were analyzed by 
one‑way ANOVA with Tukey’s post‑test. ** is P < 0.01 and *** is P < 0.001. e In vivo tumor growth inhibition rate of 4T1 tumor bearing BALB/c mice 
after the PTT with NS, AL, and LAL. f Representative photographs of 4T1 tumor bearing BALB/c mice exhibiting tumor growth at 0, 8, and 15 days
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acid (PLGA) NP demonstrated improved efficacy of 
checkpoint-blockade using anti-cytotoxic T-lymphocyte 
antigen-4 (anti-CTLA4) [70]. Huang et al. reported that 
a lipid gel depot loaded with IR820 (PTT agent) and 
anti programmed death-ligand 1 (PD-L1) antibody (ICI) 
could induce increased lymphocyte infiltration and anti-
tumor activity in “cold” tumors [71]. Lu et  al. reported 
that polydopamine based NP mediated PTT was able to 
enhance anti PD-L1 therapy by activating both innate 
and adaptive immune systems [72]. We also expect LAL 
could be further utilized for enhancement of ICI based 
on its excellent tumor targeting ability and PTT effect.
Conclusions
We developed LAL by covering AL with additional lipo-
some layer for the effective in  vivo imaging and tar-
get-specific PTT. LAL showed better stability, tumor 
targeting, and in  vitro/in vivo PTT effect than AL. We 
found that LAL has (1) high photothermal conversion 
efficiency, (2) high in vivo stability and passive targeting 
efficiency, and (3) excellent in  vitro/in vivo PTT effect. 
Also, the passive targeting ability of LAL outperformed 
previously reported Au based PTT agents. Therefore, 




Distearoyl phosphatidylcholine (DSPC) was purchased 
from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). 
1,2-Distearoyl-sn-glycero-3-phosphoethanolamine 
(methoxy(polyethylene glycol)-5000) (DSPE-PEG(5k)) 
and 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-
N-[amino(polyethylene glycol)-2000] (DSPE-PEG(2K)-
NH2 were obtained from Creative PEGworks (Chapel 
Hill, NC, USA). Cholesterol (chol), l-ascorbic acid, 
citric acid, sodium acetate, thiazolyl blue tetrazolium 
bromide, and Roswell Park Memorial Institute (RPMI) 
1640, Triton X-100, and bovine serum albumin were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Hydrogen tetrachloroaurate tetrahydrate  (HAuCl4∙4H2O) 
was acquired from Kojima Chemicals (Saitama, Japan). 
2-(p-Isothiocyanatobenzyl)-1,4,7-triazacyclononane-
N,Nʹ,Nʺ-triacetic acid trihydrochloride (p-SCN-Bn)-
NOTA (> 95%) was purchased from FutureChem Co., 
Ltd. (Seoul, Korea). Size exclusion PD-10 column 
and fetal bovine serum (FBS) were obtained from GE 
Healthcare Life Science (Buckinghamshire, UK). Radio-
instant thin layer chromatography silica gel (ITLC-SG) 
was acquired from Agilent Technologies, Inc. (Santa 
Clara, CA, USA). 4% paraformaldehyde (PFA) was pur-
chased from Biosesang (Seongnam, Korea). Phospho-
Histone H2A.X (Ser140) monoclonal antibody (3F2) and 
1,1ʹ-dioctadecyl-3,3,3ʹ,3ʹ-tetramethylindotricarbocyanine 
iodide (DiR) were purchased from Invitrogen (Carlsbad, 
CA, USA). Goat Anti-Mouse IgG H&L (Alexa Fluor 488) 
was acquired from Abcam (Cambridge, UK).  ViaFluor® 
488 Live Cell Microtubule Staining Kit was acquired 
from Biotuim (Fremont, CA, USA). Female BALB/c and 
BALB/c nude mice (6–8 weeks) were obtained from Ori-
ent Bio (Seongnam, Korea).
Instruments
All hydrodynamic sizes and zeta potential values were 
characterized by dynamic light scattering (DLS, Zeta-
sizer Nano-ZS, Malvern Instrument Ltd., Worcester-
shire, UK). Energy-Filtering Transmission Electron 
Microscope (EF-TEM, 120  kV, LIBRA 120, Carl Zeiss, 
Oberkochen, Germany) was used to confirm the nano-
structures. Absorbance and fluorescence were measured 
by a microplate reader (SYNERGY H1, BioTek, Winooski, 
VT, USA). To conduct a photothermal effect and PTT 
experiments, 808-nm NIR laser (FC-W-808-10W, CNI, 
Changchun, China) and thermal imaging camera (HT-
18, HT instrument, Faenza, Italy) were used. A confocal 
microscope (Nikon A1R, Nikon Co., Tokyo, Japan) was 
operated to observe cellular uptake. In vivo mice fluores-
cence images were obtained using in vivo imaging system 
(IVIS, IVIS Lumina X5 Imaging System, Perkin-Elmer, 
Waltham, MA, U.S). Animal PET (GENISYS, Sofie Bio-
sciences, Culver City, CA, USA) was used to observein 
vivo biodistribution images and the images were ana-
lyzed by MIMvista (MIM Software Inc.).
Preparation of liposome‑coated Au‑liposome (LAL)
2.5:1 molar ratio of DSPC and cholesterol were dissolved 
in the mixture of chloroform and methanol. The mixture 
was dried completely, and the pre-liposomal lipid film 
was formed. The lipid film was hydrated with deionized 
water (DW) and dispersed by forming multilamellar vesi-
cles. The liposomal solution was prepared after ultrasoni-
cation, and the liposome was purified with the 0.2-μm 
syringe filter and size exclusion chromatography with a 
PD-10 column. The prepared inner liposome was deco-
rated with Au using a 1% (wt/v)  HAuCl4∙4H2O solution 
and a 10% (wt/v) ascorbic acid solution, which was Au-
liposome (AL). This process occurred with a color change 
from the translucent white liposomal solution to the blu-
ish-green color solution. The outer liposomal layer with 
DSPC:chol:DSPE-PEG(5k) = 2.5:1:0.3 molar ratio was 
prepared by the same procedure as the inner liposome. 
The only difference is it was hydrated with AL suspen-
sion, not DW. Afterward, liposome coated Au-liposome 
(LAL) was purified by a syringe filter and a PD-10 col-
umn. Hydrodynamic sizes of AL and LAL were charac-
terized by DLS, and TEM images were obtained after 
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negative stain with a 2% uranyl acetate solution. Every 
zeta potential was measured in 5  mM phosphate buffer 
(pH 7.4) and repeated 12 times.
In vitro stability
The prepared AL and LAL were diluted by Au concen-
tration 4.74  μg   mL−1 in DW, phosphate-buffered saline 
(PBS), and RPMI 1640 medium containing 10% FBS and 
1% penicillin/streptomycin to demonstrate the stabilities 
in physiological conditions for 14 days at room tempera-
ture. Hydrodynamic sizes were measured at every time 
point by DLS.
In vitro photothermal effect and photothermal efficiency
Before demonstrating the photothermal effect, the 
absorbance spectra of liposome, AL, and LAL were 
measured by a microplate reader to confirm that AL and 
LAL absorbed 808-nm light. In vitro photothermal effect 
and efficiency of AL and LAL were demonstrated by the 
808-nm laser with 1 W intensity. Using a thermal imag-
ing camera, the temperature changes of DW, liposome, 
AL, and LAL under the laser irradiation were measured 
for 40 min, and the thermal images were obtained simul-
taneously. The thermal stabilities of AL and LAL demon-
strated by the on/off cycle of laser irradiation for 20 min 
and cooling down for 10 min. This cycle was repeated 4 
times, and the temperatures were measured every 30-s.
The photothermal conversion efficiency (η value) was 
calculated with Eq. 1, above mentioned.
The heat conversion was investigated by irradiating the 
AL and LAL (Au 23.7 μg  mL−1) in DW with the 1 W laser 
irradiation for 20  min. Tmax is the highest temperature 
of NP solution, and Tsur is the initial temperature of NP 
solution. Qdiss is the heat dissipation [73, 74], and I repre-
sents the power of laser. A is the absorbance at 808 nm, m 
is the weight of NP solution, and c represents the specific 
heat capacity of water. τs was determined by Eq. 2.
θ refers to the dimensionless driving force, and t repre-
sents the corresponding time.
Cytotoxicity test and in vitro PTT
4T1 breast cancer cells were cultured at 2 ×  104 cells per 
well in 96-well plates and incubated overnight at 37  °C 
under 5%  CO2. The RPMI 1640 medium containing 10% 
FBS and 1% penicillin/streptomycin was used for the 












various concentrations from 0 to 11.85  μg   mL−1. Then, 
the cells were incubated for 24  h. Cells were washed 
with DPBS to remove AL and LAL, and then the MTT 
solution was treated to the cells. Cell viability was dem-
onstrated by measuring the absorbance at 540  nm. To 
demonstrate in  vitro PTT, the 808-nm laser was irradi-
ated to the cells with 2.5 W  cm−2 for 5 min after 4 h from 
the AL and LAL addition. The other procedures were the 
same without the laser irradiation cytotoxicity test.
Cellular uptake of AL and LAL imaging
R6G was loaded in the innermost liposome to observe 
cellular uptake of AL and LAL. The R6G loaded lipo-
some was filtered using both a syringe filter and PD-10 
column. 4T1 cells were incubated overnight in con-
focal dishes at 37  °C under 5%  CO2. Both AL and LAL 
(Au 9.48 μg  mL−1) were added to the cells, and the cells 
were incubated for 4 h and then washed the AL and LAL. 
Hoechst 33342 and  ViaFluor® 488 were added for stain-
ing nuclei and cytoskeleton of the cells, and the cells 
were washed 3 times. The cellular uptake of each AL and 
LAL were observed by confocal microscopy. The cor-
rected total cell fluorescence (CTCF) was calculated from 
the fluorescence images using the free software, ImageJ 
(n = 14).
Immunofluorescence
7 ×  104 4T1 breast cancer cells were incubated in confo-
cal dishes overnight at 37  °C under 5%  CO2. Cells were 
treated with AL and LAL for 4  h and irradiated the 
2.5  W   cm−2 of 808-nm laser for 5  min. After 1  h from 
the laser irradiation, cell nuclei were stained with Hoe-
chst 33342 and then fixed with 4% paraformaldehyde at 
37  °C for 10 min. Cells were permeabilized in 0.2% Tri-
ton X-100 for 10  min and then treated with 3% BSA in 
PBS for 30 min. Phospho-Histone γ-H2A.X monoclonal 
primary antibody was added and incubated overnight at 
4 °C. After washing with PBS, cells were also added goat 
anti-mouse IgG H&L (Alexa Fluor 488) secondary anti-
body in 3% BSA for 30 min. Images of γ-H2AX foci and 
nuclei were obtained by confocal microscopy. The num-
ber of γ-H2AX foci per cell was quantified with ImageJ 
(n = 5).
Preparation of orthotopic 4T1 breast cancer model
4T1 breast cancer bearing mice were prepared for in vivo 
PET imaging, in vivo mice fluorescence imaging, photo-
thermal effect, and PTT. 4T1 cell line  (105 cells 15 μL−1 
of PBS) was injected into the left fifth nipple. In  vivo 
imaging and PTT experiment with 4T1 tumor bearing 
mice was performed when the tumor volumes were 150–
300   mm3 and 50–100   mm3. All the animal experiments 
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were approved by Institutional Animal Care and Use 
Committee at Seoul National University.
In vivo fluorescence imaging with DiR labeled AL and LAL
DiR was added when the inner liposome was prepared. 
DiR labeled inner liposome was purified by a syringe 
filter and a PD-10 column. The next procedures to pre-
pare DiR labeled AL and LAL were the same above men-
tioned. DiR labeled AL and LAL (Au 20 μg) were injected 
into the 4T1 breast cancer bearing mice (n = 4) via tail 
vein. In vivo images were acquired at 0, 2, 12, and 24 h 
from the injection, and the mice were sacrificed. Ex vivo 
fluorescence images of the tumors and main organs were 
acquired. Each tumor to liver, spleen, and lung ratio were 
analyzed statistically with a Student’s t-test, two-sided.
Radiolabeling efficiency and radiostability of LAL
For radiolabeling of LAL, the outer liposomal layer of 
LAL was composed of distearoyl phosphatidylcholine 
(DSPC), cholesterol, 1,2-Distearoyl-sn-glycero-3-phos-
phoethanolamine (methoxy(polyethylene glycol)-5000) 
(DSPE-PEG(5k)), and 1,4,7-triazacyclononane-1,4,7-
triacetic acid (NOTA) modified 1,2-Distearoyl-sn-glyc-
ero-3-phosphoethanolamine-N-[amino(polyethylene 
glycol)-2000] (DSPE-PEG(2K)). The (p-SCN-Bn)-NOTA 
was reacted with DSPE-PEG(2K)-NH2 overnight, and the 
prepared NOTA modified DSPE-PEG(2K) was added to 
the outer pre-liposomal lipid mixture. The following pro-
cedure was the same as the LAL procedure mentioned 
above. NOTA modified LAL and 64Cu (II) ion were 
reacted in pH 5 sodium acetate buffer solution at 37  °C 
for an hour. Size exclusion chromatography was con-
ducted to eliminate the free 64Cu (II) ion.
To demonstrate radiostability, 64Cu labeled LAL (64Cu-
LAL, 2  μL) and 64CuCl2 solution was loaded onto the 
ITLC-SG plate, and thin-layer chromatography (TLC) 
was conducted with a 0.1  M citric acid solution after 0 
to 24 h from a size exclusion chromatography. Radiolabe-
ling efficiency of 64Cu-LAL at each time point was meas-
ured based on the TLC result.
In vivo PET imaging and quantitative in vivo 
biodistribution analysis
64Cu-LAL (200  μL, Au 4.74  μg) was injected intrave-
nously into every mouse (n = 3) anesthetized with 2% 
isoflurane to confirm the in vivo biodistribution data and 
tumor targeting efficiency. PET images were acquired 
with an animal PET instrument. The three-dimensional 
region of interest (ROI) values of major organs (including 
heart, liver, spleen, and muscle) and tumor were analyzed 
by MIM software.
In vivo photothermal effect
To confirm the in  vivo photothermal effect, LAL and 
AL with 2.37 μg of Au (50 μL) were injected into normal 
BALB/c nude mice subcutaneously. The laser was irra-
diated to the AL and LAL injected site of each mouse 
(n = 3) anesthetized with 2% isoflurane with 2.5 W  cm−2 
laser intensities for 5 min. Each temperature was meas-
ured by a thermal imaging camera before and after the 
laser irradiation.
In vivo PTT
Prepared LAL, AL, and NS were injected into the 4T1 
breast cancer bearing mice via tail vein. The same amount 
of Au (20  μg) was loaded in AL and LAL. The 808-
nm laser was directly irradiated to the tumor site with 
2.5  W   cm−2 intensities, and the laser irradiation proce-
dures were carried out twice in this experiment, and the 
mice were anesthetized with 2% isoflurane. The first laser 
irradiation was conducted after 24  h from the iv. injec-
tion and the second laser irradiation was conducted 
after 48 h from the iv. injection. Thus, in this in vivo PTT 
experiment, there were 6 groups (n = 4) as follows: LAL 
without laser irradiation, LAL with laser irradiation, AL 
without laser irradiation, AL with laser irradiation, NS 
without laser irradiation, and NS with laser irradiation 
(NS, NS + laser, AL, AL + laser, LAL, and LAL + laser). 
Photothermal images were obtained simultaneously irra-
diating the laser, and the acquired temperatures were 
compared by one-way ANOVA with Tukey’s post-test. 
Tumor sizes were measured up to 18 days from the LAL, 
AL, and NS injection, and tumor images were obtained 
on the same day. Tumor volumes were calculated using 
the following formula,
where a and b are the larger and smaller diameters, 
respectively. After the PTT, major organs (heart, liver, 
spleen, kidney, lung, muscle, and intestine) and tumor in 
each group were paraffin sectioned, and H&E stained for 
the tissue imaging.
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